

James D Perkins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5714668/publications.pdf>

Version: 2024-02-01

309
papers

6,369
citations

76326

40
h-index

76900

74
g-index

310
all docs

310
docs citations

310
times ranked

5751
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 491-502.	4.7	547
2	First-pass metabolism of midazolam by the human intestine*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 14-24.	4.7	409
3	The biopsied donor liver: Incorporating macrosteatosis into high-risk donor assessment. <i>Liver Transplantation</i> , 2010, 16, 874-884.	2.4	299
4	Liver Transplantation for Hepatocellular Carcinoma: Impact of the MELD Allocation System and Predictors of Survival. <i>Gastroenterology</i> , 2008, 134, 1342-1351.	1.3	240
5	Impact of Cytomegalovirus in Organ Transplant Recipients in the Era of Antiviral Prophylaxis. <i>Transplantation</i> , 2006, 81, 1645-1652.	1.0	217
6	Ischemic cholangiopathy following liver transplantation from donation after cardiac death donors. <i>Liver Transplantation</i> , 2008, 14, 604-610.	2.4	207
7	The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. <i>Hepatology</i> , 1987, 7, 476-483.	7.3	200
8	Persistent hepatitis C virus infection after liver transplantation: Clinical and virological features. <i>Hepatology</i> , 1995, 22, 1-9.	7.3	169
9	Liver transplantation at the extremes of the body mass index. <i>Liver Transplantation</i> , 2009, 15, 968-977.	2.4	168
10	Productive Replication of Hepatitis C Virus in Perihepatic Lymph Nodes In Vivo: Implications of HCV Lymphotropism. <i>Gastroenterology</i> , 2006, 130, 1107-1116.	1.3	141
11	SELECTIVE BOWEL DECONTAMINATION TO DECREASE GRAM-NEGATIVE AEROBIC BACTERIAL AND CANDIDA COLONIZATION AND PREVENT INFECTION AFTER ORTHOTOPIC LIVER TRANSPLANTATION. <i>Transplantation</i> , 1988, 45, 570-574.	1.0	139
12	INFLUENCE OF POSITIVE LYMPHOCYTE CROSSMATCH AND HLA MISMATCHING ON VANISHING BILE DUCT SYNDROME IN HUMAN LIVER ALLOGRAFTS. <i>Transplantation</i> , 1988, 45, 376-379.	1.0	107
13	Optimal grade transition and selection of closed-loop controllers in a gas-phase olefin polymerization fluidized bed reactor. <i>Chemical Engineering Science</i> , 2003, 58, 3643-3658.	3.8	106
14	Simultaneous design and control optimisation under uncertainty. <i>Computers and Chemical Engineering</i> , 2000, 24, 261-266.	3.8	98
15	End-stage liver disease without hemochromatosis associated with elevated hepatic iron index. <i>Journal of Hepatology</i> , 1998, 29, 257-262.	3.7	92
16	Multigene Tracking of Hepatitis C Virus Quasispecies after Liver Transplantation: Correlation of Genetic Diversification in the Envelope Region with Asymptomatic or Mild Disease Patterns. <i>Journal of Virology</i> , 1998, 72, 10036-10043.	3.4	92
17	SPLenic ARtery ANEURYSMS IN LIVER TRANSPLANT PATIENTS. <i>Transplantation</i> , 1988, 45, 386-388.	1.0	89
18	CTLA4 Engagement is Required for Induction of Murine Liver Transplant Spontaneous Tolerance+. <i>American Journal of Transplantation</i> , 2005, 5, 978-986.	4.7	75

#	ARTICLE	IF	CITATIONS
19	PROSPECTIVE, RANDOMIZED TRIAL OF THE EFFECT OF ANTIBODY INDUCTION IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION: THREE-YEAR RESULTS1. <i>Transplantation</i> , 2004, 77, 1269-1275.	1.0	70
20	Optimization as a tool for design/control integration. <i>Computers and Chemical Engineering</i> , 1996, 20, 315-323.	3.8	68
21	Combination of Peritubular C4d and Transplant Glomerulopathy Predicts Late Renal Allograft Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 2260-2268.	6.1	66
22	Circulating Epithelial Cells in Patients with Pancreatic Lesions: Clinical and Pathologic Findings. <i>Journal of the American College of Surgeons</i> , 2015, 221, 699-707.	0.5	64
23	Outcomes in Children After Intestinal Transplant. <i>Pediatrics</i> , 2010, 125, e550-e558.	2.1	62
24	SOLUBLE INTERLEUKIN-2 RECEPTOR LEVEL AS AN INDICATOR OF LIVER ALLOGRAFT REJECTION. <i>Transplantation</i> , 1989, 47, 77-81.	1.0	61
25	Dynamics of Hepatitis C Virus Replication in Human Liver. <i>American Journal of Pathology</i> , 2003, 163, 433-444.	3.8	58
26	Acute Hepatic Failure: The Emerging Role of Orthotopic Liver Transplantation. <i>Mayo Clinic Proceedings</i> , 1989, 64, 424-428.	3.0	57
27	Persistent centrilobular necroses in hepatic allografts. <i>Human Pathology</i> , 1990, 21, 656-661.	2.0	57
28	Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: Implications for surveillance studies and new adjuvant therapies. <i>Liver Transplantation</i> , 2008, 14, 956-965.	2.4	56
29	The Role of Foxp3+ Regulatory T Cells in Liver Transplant Tolerance. <i>Transplantation Proceedings</i> , 2006, 38, 3205-3206.	0.6	54
30	Recipient and donor factors influence the incidence of graft-vs.-host disease in liver transplant patients. <i>Liver Transplantation</i> , 2007, 13, 516-522.	2.4	54
31	Clinical factors predicting readmission after orthotopic liver transplantation. <i>Liver Transplantation</i> , 2012, 18, 1037-1045.	2.4	53
32	Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 943-953.	1.5	52
33	RENAL DISEASE IN HEPATITIS C-POSITIVE LIVER TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1997, 63, 1287-1293.	1.0	52
34	Advancing the High Throughput Identification of Liver Fibrosis Protein Signatures Using Multiplexed Ion Mobility Spectrometry. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 1119-1127.	3.8	51
35	Intraoperative portal vein blood flow predicts allograft and patient survival following liver transplantation. <i>Hpb</i> , 2010, 12, 166-173.	0.3	49
36	Failure of Interferon To Prevent Recurrent Hepatitis B Infection in Hepatic Allograft. <i>Mayo Clinic Proceedings</i> , 1989, 64, 429-432.	3.0	48

#	ARTICLE	IF	CITATIONS
37	The interactions of design and control: double-effect distillation. <i>Journal of Process Control</i> , 2000, 10, 219-227.	3.3	48
38	Optimal synthesis and design of dynamic systems under uncertainty. <i>Computers and Chemical Engineering</i> , 1996, 20, S895-S900.	3.8	44
39	Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of hepatitis C following liver transplantation. <i>Tissue Antigens</i> , 1998, 52, 435-443.	1.0	41
40	Anti-CD25 mAb Administration Prevents Spontaneous Liver Transplant Tolerance. <i>Transplantation Proceedings</i> , 2006, 38, 3207-3208.	0.6	41
41	Use of Ultrasound and Cystoscopically Guided Pancreatic Allograft Biopsies and Transabdominal Renal Allograft Biopsies: Safety and Efficacy in Kidney-Pancreas Transplant Recipients. <i>Journal of Urology</i> , 1995, 153, 316-321.	0.4	40
42	USE OF A WALLSTENT IN SUCCESSFUL TREATMENT OF IVC OBSTRUCTION FOLLOWING LIVER TRANSPLANTATION. <i>Transplantation</i> , 1996, 61, 669-672.	1.0	40
43	Proteome and computational analyses reveal new insights into the mechanisms of hepatitis C virus-mediated liver disease posttransplantation. <i>Hepatology</i> , 2012, 56, 28-38.	7.3	39
44	EOSINOPHIL GRANULE MAJOR BASIC PROTEIN IN ACUTE RENAL ALLOGRAFT REJECTION. <i>Transplantation</i> , 1989, 47, 959-963.	1.0	38
45	Robust parameter estimation in on-line optimization—part I. methodology and simulated case study. <i>Computers and Chemical Engineering</i> , 1992, 16, 545-562.	3.8	37
46	PD-L1 Signal on Liver Dendritic Cells Is Critical for Foxp3+CD4+CD25+ Treg and Liver Tolerance Induction in Mice. <i>Transplantation Proceedings</i> , 2013, 45, 1853-1855.	0.6	36
47	Economic performance analysis in the design of on-line batch optimization systems. <i>Journal of Process Control</i> , 1999, 9, 61-78.	3.3	35
48	DIFFERENTIAL DIAGNOSIS OF HYPOAMYLASURIA IN PANCREAS ALLOGRAFT RECIPIENTS WITH URINARY EXOCRINE DRAINAGE. <i>Transplantation</i> , 1990, 49, 359-362.	1.0	34
49	Switchability analysis. <i>Computers and Chemical Engineering</i> , 1996, 20, 469-474.	3.8	33
50	Histologic Diagnosis of Rejection by Using. <i>American Journal of Surgical Pathology</i> , 1990, 14, 837-846.	3.7	32
51	Cyclic interdigestive pancreatic exocrine secretion: Is it mediated by neural or hormonal mechanisms?. <i>Gastroenterology</i> , 1992, 102, 1378-1384.	1.3	32
52	Economic analysis of different structures of on-line process optimization systems. <i>Computers and Chemical Engineering</i> , 1998, 22, 1257-1269.	3.8	32
53	Seeding risk following percutaneous approach to hepatocellular carcinoma. <i>Liver Transplantation</i> , 2007, 13, 1603-1607.	2.4	32
54	Plasma Glucose Concentrations During Liver Transplantation. <i>Mayo Clinic Proceedings</i> , 1989, 64, 241-245.	3.0	31

#	ARTICLE	IF	CITATIONS
55	Pre- and post-transplant therapy for hepatocellular carcinoma is associated with a lower recurrence after liver transplantation. <i>Clinical Transplantation</i> , 2009, 23, 874-881.	1.6	30
56	Kidney Biopsies May Help Predict Renal Function After Liver Transplantation. <i>Transplantation</i> , 2016, 100, 2122-2128.	1.0	30
57	Hepatitis c-associated glomerular disease in liver transplant recipients. <i>Liver Transplantation</i> , 1995, 1, 166-175.	1.8	29
58	Saying "no" to obese living liver donors: Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Nakamuta M, Morizono S, Soejima Y, Yoshizumi T, Aishima S, Takasugi S, et al. <i>Transplantation</i> 2005;80:608-612. <i>Liver Transplantation</i> , 2006, 12, 1012-1016.	2.4	29
59	PD-L1/PD-1 Signal Deficiency Promotes Allogeneic Immune Responses and Accelerates Heart Allograft Rejection. <i>Transplantation</i> , 2008, 86, 836-844.	1.0	29
60	Risk stratification of kidneys from donation after cardiac death donors and the utility of machine perfusion. <i>Clinical Transplantation</i> , 2011, 25, E530-40.	1.6	29
61	Flexibility analysis and design of dynamic processes with stochastic parameters. <i>Computers and Chemical Engineering</i> , 1998, 22, S817-S820.	3.8	27
62	Size mismatch in deceased donor liver transplantation and its impact on graft survival. <i>Clinical Transplantation</i> , 2019, 33, e13662.	1.6	26
63	Optimal design and control of a high-purity industrial distillation system. <i>Computers and Chemical Engineering</i> , 2001, 25, 141-150.	3.8	25
64	Should liver transplantation in patients with model for end-stage liver disease scores ≥ 14 be avoided? A decision analysis approach. <i>Liver Transplantation</i> , 2009, 15, 242-254.	2.4	25
65	Computer generation of process models. <i>Computers and Chemical Engineering</i> , 1996, 20, 635-639.	3.8	24
66	IMMUNOHISTOLOGIC LABELING AS AN INDICATOR OF LIVER ALLOGRAFT REJECTION. <i>Transplantation</i> , 1987, 43, 105-107.	1.0	23
67	Endotheliitis in Hepatic Allografts. <i>Mayo Clinic Proceedings</i> , 1989, 64, 545-554.	3.0	23
68	IMMUNOSUPPRESSIVE THERAPY AS A DETERMINANT OF TRANSPLANTATION OUTCOMES. <i>Transplantation</i> , 1993, 55, 1297-1305.	1.0	23
69	Using Root Cause Analysis to Improve Survival in a Liver Transplant Program. <i>Journal of Surgical Research</i> , 2005, 129, 6-16.	1.6	23
70	Impact of obesity on children undergoing liver transplantation. <i>Liver Transplantation</i> , 2010, 16, 1296-1302.	2.4	23
71	REVERSIBLE CYCLOSPORINE ARTERIOLOPATHY. <i>Transplantation</i> , 1992, 54, 732-733.	1.0	22
72	Recent trends in liver transplantation for alcoholic liver disease in the United States. <i>World Journal of Hepatology</i> , 2017, 9, 1315-1321.	2.0	22

#	ARTICLE	IF	CITATIONS
73	Rescue of Acute Portal Vein Thrombosis After Liver Transplantation Using a Cavoportal Shunt at Re-transplantation. American Journal of Transplantation, 2001, 1, 284-287.	4.7	21
74	Role of the Liver in Peripheral Tolerance: Induction Through Oral Antigen Feeding. American Journal of Transplantation, 2004, 4, 1574-1582.	4.7	21
75	Hepatic artery thrombosis and liver malignancy in pediatric liver transplantation. Journal of Pediatric Surgery, 2012, 47, 1255-1260.	1.6	21
76	Living liver donation improves patient and graft survival in the pediatric population. Pediatric Transplantation, 2019, 23, e13318.	1.0	20
77	New Evidence Supporting Increased Use of Split Liver Transplantation. Transplantation, 2020, 104, 299-307.	1.0	19
78	Identifying and solving problems in engineering design. Studies in Higher Education, 1989, 14, 169-181.	4.5	18
79	EVIDENCE THAT THE SOLUBLE INTERLEUKIN 2 RECEPTOR LEVEL MAY DETERMINE THE OPTIMAL TIME FOR CYSTOSCOPICALLY-DIRECTED BIOPSY IN PANCREATOCODUODENAL ALLOGRAFT RECIPIENTS. Transplantation, 1990, 49, 363-366.	1.0	18
80	The natural history of untreated focal allograft rejection in liver transplant recipients. Liver Transplantation, 1996, 2, 154-160.	1.8	18
81	Pancreas Transplantation at Mayo: III. Multidisciplinary Management. Mayo Clinic Proceedings, 1990, 65, 496-508.	3.0	17
82	Optimal design and control of an industrial distillation system. Computers and Chemical Engineering, 1999, 23, S875-S878.	3.8	16
83	The explicit control law for hybrid systems via parametric programming. , 0, , .		16
84	Acetaminophen sets records in the United States: Number 1 analgesic and number 1 cause of acute liver failure. Liver Transplantation, 2006, 12, 682-686.	2.4	15
85	Investigation of Putative Multisubtype Hepatitis C Virus Infections In Vivo by Heteroduplex Mobility Analysis of Core/Envelope Subgenomes. Journal of Virology, 2008, 82, 7524-7532.	3.4	15
86	Another formula to determine the prognosis of patients with acute liver failure. Liver Transplantation, 2009, 15, 986-991.	2.4	15
87	Efficient solution of design problems using a sequential-modular flowsheeting programme. Computers and Chemical Engineering, 1979, 3, 375-381.	3.8	14
88	Identifying the futile pediatric liver re-transplant in the PELD era. Pediatric Transplantation, 2010, 14, 1019-1029.	1.0	14
89	Outcomes in children with intestinal failure following listing for intestinal transplant. Journal of Pediatric Surgery, 2010, 45, 100-107.	1.6	14
90	Are we reporting the same thing?. Liver Transplantation, 2007, 13, 465-6.	2.4	14

#	ARTICLE	IF	CITATIONS
91	Genetic diversity of hepatitis C virus predicts recurrent disease after liver transplantation. <i>Virology</i> , 2010, 402, 248-255.	2.4	13
92	Immunohistologic Pattern of the Portal T-Lymphocyte Infiltration in Hepatic Allograft Rejection. <i>Mayo Clinic Proceedings</i> , 1989, 64, 565-569.	3.0	12
93	Economic analysis of different structures of on-line process optimization systems. <i>Computers and Chemical Engineering</i> , 1996, 20, S551-S556.	3.8	12
94	The impact of consecutive operations on survival after liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 907-914.	2.4	12
95	Techniques to ensure adequate portal flow in the presence of splenorenal shunts. <i>Liver Transplantation</i> , 2007, 13, 767-8.	2.4	12
96	An implementation of quasi-newton methods for solving sets of nonlinear equations. <i>Computers and Chemical Engineering</i> , 1988, 12, 767-776.	3.8	11
97	Pancreas Transplantation at Mayo: II. Operative and Perioperative Management. <i>Mayo Clinic Proceedings</i> , 1990, 65, 483-495.	3.0	11
98	Uterine Leiomyoma in an Adolescent Female. <i>Journal of the National Medical Association</i> , 2009, 101, 611-613.	0.8	11
99	Living Donation Versus Donation After Circulatory Death Liver Transplantation for Low Model for End-Stage Liver Disease Recipients. <i>Liver Transplantation</i> , 2019, 25, 580-587.	2.4	11
100	Clinical Impact and Risk Factors of Portal Vein Thrombosis for Patients on Wait List for Liver Transplant. <i>Experimental and Clinical Transplantation</i> , 2018, 16, 166-171.	0.5	11
101	Robust parameter estimation in on-line optimization—part 2. Application to an industrial process. <i>Computers and Chemical Engineering</i> , 1993, 17, 663-669.	3.8	10
102	Use of an automated clinical management system improves outpatient immunosuppressive care following liver transplantation. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2010, 17, 396-402.	4.4	10
103	End-of-Life Care among US Adults with ESKD Who Were Waitlisted or Received a Kidney Transplant, 2005–2014. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2424-2433.	6.1	10
104	THE EFFECT OF SOMATOSTATIN 201–995 ON THE EARLY COURSE OF PORCINE PANCREATODUODENAL ALLOTRANSPLANTATION. <i>Transplantation</i> , 1991, 51, 31-36.	1.0	9
105	Performance analysis of on-line batch optimization systems. <i>Computers and Chemical Engineering</i> , 1997, 21, S867-S872.	3.8	9
106	Optimal grade transition campaign scheduling in a gas-phase polyolefin FBR using mixed integer dynamic optimization. <i>Computer Aided Chemical Engineering</i> , 2003, 14, 71-76.	0.5	9
107	Acute liver failure in children: They really are not just small adults: Acute liver failure in children: The first 348 patients in the Pediatric Acute Liver Failure Study Group. Squires RH Jr, Shneider BL, Bucuvalas J, Alonso E, Sokol RJ, Narkewicz, et al. <i>J Pediatr</i> 2006;148:652-658. <i>Liver Transplantation</i> , 2006, 12, 1715-1719.	2.4	9
108	Molecular Signatures of Recurrent Hepatocellular Carcinoma Secondary to Hepatitis C Virus following Liver Transplantation. <i>Journal of Transplantation</i> , 2013, 2013, 1-14.	0.5	9

#	ARTICLE	IF	CITATIONS
109	Listing practices and graft utilization of hepatitis Câ€“positive deceased donors in liver and kidney transplant. <i>Surgery</i> , 2019, 166, 102-108.	1.9	9
110	Sparse newton-like methods in equation oriented flowsheeting. <i>Computers and Chemical Engineering</i> , 1988, 12, 791-805.	3.8	8
111	Scale invariant quasi-Newton methods for the solution of nonlinear equations. <i>Computers and Chemical Engineering</i> , 1988, 12, 91-97.	3.8	8
112	SEQUENTIAL HISTOPATHOLOGIC CHANGES IN PANCREATOCODUODENAL ALLOGRAFT REJECTION IN DOGS. <i>Transplantation</i> , 1989, 48, 764-768.	1.0	8
113	Liver transplantation worldwide. <i>Liver Transplantation</i> , 2006, 12, 159-162.	2.4	8
114	Association of Donor and Recipient Cytomegalovirus Serostatus on Graft and Patient Survival in Liver Transplant Recipients. <i>Liver Transplantation</i> , 2021, 27, 1302-1311.	2.4	8
115	Willingness to Consider Increased-Risk Donors: A Single-Center Experience in Kidney Transplantation. <i>Annals of Transplantation</i> , 2018, 23, 387-392.	0.9	8
116	Pancreas Transplantation at Mayo: I. Patient Selection. <i>Mayo Clinic Proceedings</i> , 1990, 65, 475-482.	3.0	7
117	Enhancement of NKT Cells and Increase in Regulatory T Cells Results in Improved Allograft Survival. <i>Journal of Surgical Research</i> , 2006, 134, 10-21.	1.6	7
118	Immediate tracheal extubation following liver transplantation: Fast track in liver transplantation: 5 years' experience. Biancofiore G, Bindi ML, Romanelli AM, Boldrini A, BisÃ M, Esposito M, Urbani L, Catalano G, Mosca F, Filippini F. <i>Eur J Anaesthesiol</i> 2005;22:584â€“590.. <i>Liver Transplantation</i> , 2006, 12, 883-887.	2.4	7
119	Incisional hernia repair after liver transplantation: A second editorial look. <i>Liver Transplantation</i> , 2007, 13, 302-305.	2.4	7
120	Recurrent hepatocellular carcinoma is a problem we need to tackle. <i>Liver Transplantation</i> , 2007, 13, 1057-1061.	2.4	7
121	Contemporary patterns in kidney graft survival from donors after circulatory death in the United States. <i>PLoS ONE</i> , 2020, 15, e0233610.	2.5	7
122	Acute Graftâ€“Versusâ€“Host Disease After Orthotopic Liver Transplantation: Predicting This Rare Complication Using Machine Learning. <i>Liver Transplantation</i> , 2022, 28, 407-421.	2.4	7
123	Screening for portopulmonary hypertension. <i>Liver Transplantation</i> , 2007, 13, 463-467.	2.4	6
124	Incisional hernia following liver transplantation: Today's incidence and causes of this pesky problem. <i>Liver Transplantation</i> , 2007, 13, 1339-1342.	2.4	6
125	Hyperkalemia and liver transplantation. <i>Liver Transplantation</i> , 2008, 14, 252-256.	2.4	6
126	The <sc>HALOS</sc>â€“<sc>ND</sc> model: a step in the journey of predicting hospital length of stay after liver transplantation. <i>Clinical Transplantation</i> , 2013, 27, 809-822.	1.6	6

#	ARTICLE	IF	CITATIONS
127	Livers From Pediatric Donation After Circulatory Death Donors Represent a Viable and Underutilized Source of Allograft. <i>Liver Transplantation</i> , 2020, 26, 1138-1153.	2.4	6
128	Do funding sources influence long-term patient survival in pediatric liver transplantation?. <i>Pediatric Transplantation</i> , 2021, 25, e13887.	1.0	6
129	RECOMBINANT HUMAN TUMOR NECROSIS FACTOR RECEPTOR Fc FUSION PROTEIN THERAPY IN KIDNEY TRANSPLANT RECIPIENTS UNDERGOING OKT3 INDUCTION THERAPY ^{1,2} . <i>Transplantation</i> , 1998, 66, 1732-1735.	1.0	6
130	The impact of the COVID-19 pandemic on medical student education: Implementation and outcome of a virtual general surgery curriculum. <i>American Journal of Surgery</i> , 2022, , .	1.8	6
131	Robust model-based Controllers via Parametric Programming. <i>Computer Aided Chemical Engineering</i> , 2002, 10, 541-546.	0.5	5
132	Thrombolysis for early hepatic artery thrombosis: Definitive therapy or diagnostic aid?. <i>Liver Transplantation</i> , 2007, 13, 927-931.	2.4	5
133	Balloon dilation only versus balloon dilation plus stenting for posttransplantation biliary strictures. <i>Liver Transplantation</i> , 2009, 15, 106-110.	2.4	5
134	Burden of excess mortality after implementation of the new kidney allocation system may be borne disproportionately by middle-aged recipients. <i>PLoS ONE</i> , 2019, 14, e0210589.	2.5	5
135	Living vs deceased donor liver transplantation in cholestatic liver disease: An analysis of the OPTN database. <i>Clinical Transplantation</i> , 2020, 34, e14031.	1.6	5
136	The updating of LU factors in quasi-Newton methods. <i>Computers and Chemical Engineering</i> , 1986, 10, 241-247.	3.8	4
137	Optimization-Based Methodologies for Integrating Design and Control in Cryogenic Plants. <i>Computer Aided Chemical Engineering</i> , 2002, 10, 331-336.	0.5	4
138	The explicit model-based control law for continuous time systems via parametric programming - INV5105. , 2002, , .		4
139	Metabolic syndrome: A new view of some familiar transplant risks. <i>Liver Transplantation</i> , 2006, 12, 485-489.	2.4	4
140	Aprotinin: Effective, but risky?. <i>Liver Transplantation</i> , 2006, 12, 1293-1297.	2.4	4
141	The influence of CTLA-4 gene polymorphisms on liver transplant outcomes. <i>Liver Transplantation</i> , 2006, 12, 1552-1556.	2.4	4
142	Treatment of Small-For-Size Syndrome. <i>Liver Transplantation</i> , 2008, 14, 571-575.	2.4	4
143	Risk Factors for Developing Ischemic-Type Biliary Lesions After Liver Transplantation. <i>Liver Transplantation</i> , 2009, 15, 1882-1887.	2.4	4
144	Utilization of Standard Criteria Donor and Expanded Criteria Donor Kidneys After Kidney Allocation System Implementation. <i>Annals of Transplantation</i> , 2018, 23, 691-703.	0.9	4

#	ARTICLE	IF	CITATIONS
145	Three-year follow-up of aviremic hepatitis C-positive kidneys. American Journal of Transplantation, 2019, 19, 3212-3213.	4.7	4
146	Machine Perfusion Decreases Delayed Graft Function in Donor Grafts With High Kidney Donor Profile Index. Experimental and Clinical Transplantation, 2021, 19, 8-13.	0.5	4
147	Evolving treatment of biliary strictures following liver transplantation. Liver Transplantation, 2007, 13, 1605-7.	2.4	4
148	An Industrial Case Study in Simultaneous Design and Control using Mixed-Integer Dynamic Optimization. Computer Aided Chemical Engineering, 2002, 10, 163-168.	0.5	3
149	Left ventricular dysfunction: A hidden risk in patients undergoing liver transplantation. Liver Transplantation, 2007, 13, 165-169.	2.4	3
150	Another patient with an umbilical hernia and massive ascites: What to do?. Liver Transplantation, 2008, 14, 110-114.	2.4	3
151	Treatment of an elderly patient with hepatocellular carcinoma: Counseling from the patient's point of view. Liver Transplantation, 2012, 18, 391-394.	2.4	3
152	Outcomes after combined liver-kidney transplant vs. kidney transplant followed by liver transplant. Clinical Transplantation, 2015, 29, 60-66.	1.6	3
153	Unintended Consequences in Use of Increased Risk Donor Kidneys in the New Kidney Allocation Era. Transplantation Proceedings, 2018, 50, 14-19.	0.6	3
154	The impact of public health service increased risk donors in pediatric liver transplantation. Pediatric Transplantation, 2020, 24, e13712.	1.0	3
155	Design of robust model-based tracking controllers via parametric programming. , 0, , .		3
156	Adrenal failure in liver transplant patients: does steroid-free immunosuppression place recipients at risk for an adrenal crisis?. Liver Transplantation, 2006, 12, 160-2.	2.4	3
157	Use of Aspergillus galactomannan enzyme-linked immunosorbent assay (ELISA) in liver transplant patients. Liver Transplantation, 2007, 13, 304-5.	2.4	3
158	Influence of obesity with concurrent diseases on liver transplant survival. Liver Transplantation, 2007, 13, 928-9.	2.4	3
159	Transplanted patients with combined hepatocellular-cholangiocarcinoma: now what?. Liver Transplantation, 2007, 13, 1465-6.	2.4	3
160	Canine Pancreaticoduodenal Allotransplantation: A Preparation for Human Pancreatic Transplantation. Journal of Investigative Surgery, 1988, 1, 97-106.	1.3	2
161	Diversion of the gastroduodenal vein: an in situ model of systemic insulin drainage. Diabetes Research and Clinical Practice, 1989, 7, 109-114.	2.8	2
162	Experimental use of high-frequency ultrasound to image bowel wall after porcine intestinal transplantation. Journal of Pediatric Surgery, 1993, 28, 591-596.	1.6	2

#	ARTICLE	IF	CITATIONS
163	The amazing regenerative powers of the liver. Liver Transplantation, 2006, 12, 1431-1434.	2.4	2
164	Reply: Distinguishing between hepatic portal vein gas and pneumo(aero)bilia. Liver Transplantation, 2007, 13, 1477-1477.	2.4	2
165	Who is at risk for developing cytomegalovirus (CMV) infection following liver transplantation?. Liver Transplantation, 2007, 13, 1195-1198.	2.4	2
166	Reply: Geographic disparities and deceased donor liver transplantation within a single UNOS region. Liver Transplantation, 2007, 13, 1761-1761.	2.4	2
167	Platelet transfusions have a negative impact on liver transplant survival. Liver Transplantation, 2008, 14, 701-705.	2.4	2
168	When is a liver transplant futile?. Liver Transplantation, 2008, 14, 899-904.	2.4	2
169	Infrahepatic cavocavostomy: Expanding the armamentarium for the liver transplant surgeon. Liver Transplantation, 2009, 15, 1365-1369.	2.4	2
170	D-MELD risk capping improves post-transplant and overall mortality under markov microsimulation. World Journal of Transplantation, 2014, 4, 206.	1.6	2
171	Hepatic venous outflow obstruction after piggyback orthotopic liver transplantation. Liver Transplantation, 2006, 12, 159-60.	2.4	2
172	Steroid use in liver transplantation: none, perioperative, or full course. Liver Transplantation, 2006, 12, 1294-5.	2.4	2
173	Incidence of portal vein complications following liver transplantation. Liver Transplantation, 2008, 14, 1813-5.	2.4	2
174	Defatting the fatty liver with normothermic perfusion of the liver allograft. Liver Transplantation, 2009, 15, 1366-7.	2.4	2
175	Exploring the Influence of Gender on Surgical Clerkship Grades and Test Scores: A Single Institution, Multisite Comparison. Journal of Surgical Education, 2022, 79, 1132-1139.	2.5	2
176	Optimizing control of a refinery gas-tail. Computers and Chemical Engineering, 1993, 17, 301-308.	3.8	1
177	Liver sinusoidal endothelial cells: Their unique role in immune tolerance. Liver Transplantation, 2006, 12, 1900-1903.	2.4	1
178	Optical coherence tomography: Expanding use in the bile duct. Liver Transplantation, 2007, 13, 765-768.	2.4	1
179	Rh blood group and liver transplantation. Liver Transplantation, 2007, 13, 1463-1467.	2.4	1
180	Cancer stem cells in the blood: Possible therapeutic implications. Liver Transplantation, 2008, 14, 1060-1064.	2.4	1

#	ARTICLE	IF	CITATIONS
181	Alternative source of inflow to the donor hepatic arteries. Liver Transplantation, 2008, 14, 1216-1220.	2.4	1
182	Biliary tract complications: The most common postoperative complication in living liver donors. Liver Transplantation, 2008, 14, 1372-1377.	2.4	1
183	Patient Transplant Survival Not Influenced by Type of Liver Graft. Liver Transplantation, 2008, 14, 1533-1537.	2.4	1
184	Continuing Success with Down-Staging of Hepatocellular Carcinoma. Liver Transplantation, 2008, 14, 1810-1815.	2.4	1
185	Timing of liver transplantation following transjugular intrahepatic portosystemic shunt in patients with Budd-Chiari syndrome. Liver Transplantation, 2009, 15, 341-346.	2.4	1
186	Biodegradable Bile Duct Stents: Use in Liver Transplantation?. Liver Transplantation, 2009, 15, 440-445.	2.4	1
187	Can we mitigate the effects of simultaneous liver-kidney transplantation through increased utilization of HCV-positive donors?. American Journal of Transplantation, 2018, 18, 2604-2605.	4.7	1
188	NKT Cells in the Liver are Important for Peripheral Tolerance Induction. Transplantation, 2018, 102, S694.	1.0	1
189	Adults transplanted as children as retransplant candidates: Analysis of outcomes support optimism in a population mislabeled as high risk. Clinical Transplantation, 2020, 34, e13880.	1.6	1
190	Effect of Donor Transaminase Levels on Graft Survival Following Liver Transplant: An Analysis of the Organ Procurement and Transplantation Network Database. Experimental and Clinical Transplantation, 2021, 19, 250-258.	0.5	1
191	Cyclic interdigestive pancreatic exocrine secretion: Is it mediated by neural or hormonal mechanisms?. Gastroenterology, 1992, 102, 1378-1384.	1.3	1
192	Building a Utility-based Liver Allocation Model in Preparation for Continuous Distribution. Transplantation Direct, 2022, 8, e1282.	1.6	1
193	Percutaneous transhepatic balloon dilation for portal venous stenosis. Liver Transplantation, 2006, 12, 321-2.	2.4	1
194	The expanding role of nanoparticles in the treatment of liver disease. Liver Transplantation, 2007, 13, 167-8.	2.4	1
195	C4d deposits as a possible marker for acute cellular liver rejection. Liver Transplantation, 2007, 13, 303-4.	2.4	1
196	Clostridium difficile colitis associated with other complications following liver transplantation. Liver Transplantation, 2008, 14, 253-4.	2.4	1
197	Immunosuppressive therapy and inflammatory bowel disease after transplantation. Liver Transplantation, 2008, 14, 1812-3.	2.4	1
198	Is there any benefit to laparoscopic liver resection for hepatocellular carcinoma if a salvage liver transplant is needed later?. Liver Transplantation, 2009, 15, 813-4.	2.4	1

#	ARTICLE	IF	CITATIONS
199	Indications for chronic albumin infusion. Liver Transplantation, 2006, 12, 320-323.	2.4	0
200	Reply to: Which is the best timing of bile duct division in living liver donor surgery?. Liver Transplantation, 2007, 13, 1206-1206.	2.4	0
201	Reply to: Selecting patients with hepatocellular carcinoma for transplantation. Liver Transplantation, 2007, 13, 1204-1204.	2.4	0
202	Venous outflow obstruction in liver transplantation is associated with the anastomotic technique. Liver Transplantation, 2007, 13, 1751-1755.	2.4	0
203	Preemptive treatment of fungal infection: has its time arrived in liver transplantation?. Liver Transplantation, 2008, 14, 380-384.	2.4	0
204	Accuracy of detecting hepatocellular carcinomas before liver transplantation. Liver Transplantation, 2008, 14, 1675-1679.	2.4	0
205	Systematic review on preventing bacterial sepsis and wound complications in liver transplant patients. Liver Transplantation, 2009, 15, 255-259.	2.4	0
206	The extent of hepatectomy depends on the preoperative model for end-stage liver disease score. Liver Transplantation, 2009, 15, 551-555.	2.4	0
207	Safety of invasive procedures in end-stage liver disease patients. Liver Transplantation, 2009, 15, 656-661.	2.4	0
208	Use of transjugular intrahepatic portosystemic shunts after liver transplantation. Liver Transplantation, 2009, 15, 810-815.	2.4	0
209	A new clinical method to measure hepatic microcirculation. Liver Transplantation, 2009, 15, 1149-1153.	2.4	0
210	Reversibility of posttransplantation diabetes mellitus following liver transplantation. Liver Transplantation, 2009, 15, 1631-1636.	2.4	0
211	Looking Beyond the Test. American Journal of the Medical Sciences, 2013, 346, 234-235.	1.1	0
212	Impact of Insurance Status on Outcomes of Children Undergoing Liver Transplantation. Journal of the American College of Surgeons, 2019, 229, e17.	0.5	0
213	Expanding Blood Type A2B Liver Transplantation: An Alternative for High Model for End-Stage Liver Disease Score Patients. Liver Transplantation, 2020, 26, 1532-1533.	2.4	0
214	Donor-Recipient BSA Matching Is Prognostically Significant in Solitary and En Bloc Kidney Transplantation From Pediatric Circulatory Death Donors. Transplantation Direct, 2021, 7, e733.	1.6	0
215	Choosing Control Structures for Continuous Processes based on Economics. , 1990, , .		0
216	Resection margin distance in extrahepatic cholangiocarcinoma: How much is enough?. Journal of Clinical Oncology, 2019, 37, 455-455.	1.6	0

#	ARTICLE	IF	CITATIONS
217	Donor CMV Reactivation as a Novel Risk Factor for CMV Replication in Seropositive Liver Transplant Recipients. <i>Transplantation Direct</i> , 2021, 7, e637.	1.6	0
218	The hemodynamics of cirrhosis and the development of hepatorenal syndrome. <i>Liver Transplantation</i> , 2006, 12, 162.	2.4	0
219	Hemochromatosis and liver transplant survival. <i>Liver Transplantation</i> , 2006, 12, 322.	2.4	0
220	Infection by proxy: the role of chimeric mice in HBV and HCV research. <i>Liver Transplantation</i> , 2006, 12, 323.	2.4	0
221	Quality takes center stage in transplantation. <i>Liver Transplantation</i> , 2006, 12, 486-7.	2.4	0
222	Increasing the liver donor pool through donation after cardiac death. <i>Liver Transplantation</i> , 2006, 12, 487-8.	2.4	0
223	Predicting posttransplantation infection risk with gene polymorphisms. <i>Liver Transplantation</i> , 2006, 12, 488-9.	2.4	0
224	Old foe learns new tricks. <i>Liver Transplantation</i> , 2006, 12, 683.	2.4	0
225	Genetics or environment?. <i>Liver Transplantation</i> , 2006, 12, 684.	2.4	0
226	Alternative approaches to evaluating cirrhotic patients for laparoscopic cholecystectomy. <i>Liver Transplantation</i> , 2006, 12, 684-6.	2.4	0
227	Polypropylene mesh for hernia repair following transplantation. <i>Liver Transplantation</i> , 2006, 12, 884-5.	2.4	0
228	To biopsy or not to biopsy?. <i>Liver Transplantation</i> , 2006, 12, 885-6.	2.4	0
229	Treatment strategies for posttransplant lymphoproliferative disorder. <i>Liver Transplantation</i> , 2006, 12, 1013-4.	2.4	0
230	Intensive insulin therapy improves survival in critically ill patients: how does it work?. <i>Liver Transplantation</i> , 2006, 12, 1014-5.	2.4	0
231	Tracking immune cells during organ rejection. <i>Liver Transplantation</i> , 2006, 12, 1015-6.	2.4	0
232	A new reason for intraoperative blood flow measurement: improving liver allograft function. <i>Liver Transplantation</i> , 2006, 12, 1295-6.	2.4	0
233	Another dendritic cell enters the transplant story. <i>Liver Transplantation</i> , 2006, 12, 1296-7.	2.4	0
234	A modified stenting procedure for bile duct reconstruction. <i>Liver Transplantation</i> , 2006, 12, 1431-2.	2.4	0

#	ARTICLE	IF	CITATIONS
235	Another donor derived pathogen to watch out for. Liver Transplantation, 2006, 12, 1432-3.	2.4	0
236	Hepatic arterial vasospasm early after liver transplantation?. Liver Transplantation, 2006, 12, 1433-4.	2.4	0
237	Innate immunity involved in the pathogenesis of nonalcoholic steatohepatitis. Liver Transplantation, 2006, 12, 1553-4.	2.4	0
238	Using extended criteria donor (ECD) livers: three strikes and you're almost out. Liver Transplantation, 2006, 12, 1554-5.	2.4	0
239	Abdominal compartment syndrome: is the liver involved?. Liver Transplantation, 2006, 12, 1555-6.	2.4	0
240	Influence of the liver graft on post-transplantation hepatitis C antiviral therapy. Liver Transplantation, 2007, 13, 166-7.	2.4	0
241	"Tiny bubbles in our livers". Liver Transplantation, 2007, 13, 168-9.	2.4	0
242	Help needed for pretransplant depression. Liver Transplantation, 2007, 13, 303.	2.4	0
243	Recurrence of hepatocellular carcinoma: it's in the genes?. Liver Transplantation, 2007, 13, 464-5.	2.4	0
244	The evolution of caval implantation in liver transplantation. Liver Transplantation, 2007, 13, 466-7.	2.4	0
245	A new culture system to study hepatitis C virus. Liver Transplantation, 2007, 13, 765-6.	2.4	0
246	Hepatocellular resectability depends on the "Eye of the Beholder". Liver Transplantation, 2007, 13, 766-7.	2.4	0
247	Liver volume is critical: how best to gauge size. Liver Transplantation, 2007, 13, 929-30.	2.4	0
248	Irradiation of blood products: do we need to do that?. Liver Transplantation, 2007, 13, 930-1.	2.4	0
249	Expanding role of minimally invasive aspiration biopsy after liver transplantation. Liver Transplantation, 2007, 13, 1198.	2.4	0
250	Access to liver transplantation: still a controversial issue. Liver Transplantation, 2007, 13, 1340-1.	2.4	0
251	Lipid blood levels and neurological events in liver transplant patients. Liver Transplantation, 2007, 13, 1341-2.	2.4	0
252	Evasive nature of the hepatitis C virus. Liver Transplantation, 2007, 13, 1342.	2.4	0

#	ARTICLE	IF	CITATIONS
253	Exosomes?. Liver Transplantation, 2007, 13, 1466-7.	2.4	0
254	Early Development of nanoprobes for diagnostic imaging. Liver Transplantation, 2007, 13, 1604.	2.4	0
255	Quality of life after liver transplantation for acute hepatic failure. Liver Transplantation, 2007, 13, 1604-5.	2.4	0
256	Profound thrombocytopenia immediately following liver transplantation. Liver Transplantation, 2007, 13, 1753-4.	2.4	0
257	A simple treatment to prevent ischemia-reperfusion injury of the liver. Liver Transplantation, 2007, 13, 1755.	2.4	0
258	Contaminated salvaged blood in liver transplant patients. Liver Transplantation, 2008, 14, 111-2.	2.4	0
259	Avascular necrosis: a problem for liver transplant patients?. Liver Transplantation, 2008, 14, 112-3.	2.4	0
260	Liver Allocation in the United Kingdom. Liver Transplantation, 2008, 14, 113-4.	2.4	0
261	Models for predicting graft and patient survival and hepatitis C virus recurrence after liver transplantation. Liver Transplantation, 2008, 14, 254-55.	2.4	0
262	Estimating life-years: enter the argument to use split livers versus whole livers. Liver Transplantation, 2008, 14, 255-56.	2.4	0
263	The etiology of portal vein thrombosis in patients with hepatocellular carcinoma requires a vigilant diagnostic approach. Liver Transplantation, 2008, 14, 572-3.	2.4	0
264	Different liver transplant survival rates across the pond. Liver Transplantation, 2008, 14, 573-4.	2.4	0
265	Massive pulmonary embolism during liver transplantation. Liver Transplantation, 2008, 14, 575.	2.4	0
266	Have you seen a liver transplant patient with a cytomegalovirus-associated ophthalmologic complication?. Liver Transplantation, 2008, 14, 702-3.	2.4	0
267	How do you perform your hepatic arterial anastomosis? Traditional or straight?. Liver Transplantation, 2008, 14, 703-4.	2.4	0
268	The cost of liver transplant complications. Liver Transplantation, 2008, 14, 704-5.	2.4	0
269	Computerized care for transplant patients computerized alerts improve outpatient laboratory monitoring of transplant patients. Liver Transplantation, 2008, 14, 1217-8.	2.4	0
270	Another chapter involving plasmacytoid dendritic cells and immunologic tolerance. Liver Transplantation, 2008, 14, 1218-9.	2.4	0

#	ARTICLE	IF	CITATIONS
271	Sinusoidal obstructive syndrome: a rare and stressful indication for liver transplantation. Liver Transplantation, 2008, 14, 1219-20.	2.4	0
272	Evolution and standardization of microchimerism detection techniques: potential new discoveries?. Liver Transplantation, 2008, 14, 1373-4.	2.4	0
273	Another cardiac output device for study during liver transplantation. Liver Transplantation, 2008, 14, 1374-5.	2.4	0
274	Surgical Dogma challenged in liver transplantation for hepatocellular carcinoma. Liver Transplantation, 2008, 14, 1376-7.	2.4	0
275	Chronic complex bile duct injury: proceed to liver transplantation or another corrective operation. Liver Transplantation, 2008, 14, 1534-5.	2.4	0
276	Molecular markers for predicting hepatocellular carcinoma recurrence following liver transplantation. Liver Transplantation, 2008, 14, 1535-6.	2.4	0
277	Colonoscopic surveillance following liver transplantation. Liver Transplantation, 2008, 14, 1536-7.	2.4	0
278	Predicting cost in liver transplantation. Liver Transplantation, 2008, 14, 1676-7.	2.4	0
279	How old is too old to receive a living donor liver?. Liver Transplantation, 2008, 14, 1677-8.	2.4	0
280	The methods used to diagnose invasive aspergillosis in the liver transplant recipient continue to evolve. Liver Transplantation, 2008, 14, 1678-9.	2.4	0
281	What prophylaxis schedule should we use for Pneumocystis jiroveci pneumonia in our liver transplant recipients?. Liver Transplantation, 2008, 14, 1811-2.	2.4	0
282	Cost of liver transplantation. Liver Transplantation, 2009, 15, 342-3.	2.4	0
283	Immunosuppressive strategies to prevent hepatitis C recurrence. Liver Transplantation, 2009, 15, 343-5.	2.4	0
284	Longer waiting times for obese liver transplant patients. Liver Transplantation, 2009, 15, 345-6.	2.4	0
285	Methicillin-resistant staphylococcus aureus in liver programs. Liver Transplantation, 2009, 15, 441-2.	2.4	0
286	Another comparison between University of Wisconsin solution and histidine-tryptophan-ketoglutarate solution for liver preservation. Liver Transplantation, 2009, 15, 443-4.	2.4	0
287	The various functions of CD4+ Foxp3+ regulatory T cells in liver disease and transplantation. Liver Transplantation, 2009, 15, 444-5.	2.4	0
288	Acute physiology and chronic health evaluation scores for predicting outcomes in urgent liver transplants. Liver Transplantation, 2009, 15, 657-8.	2.4	0

#	ARTICLE	IF	CITATIONS
289	The evolving story of new food allergies following liver transplantation. Liver Transplantation, 2009, 15, 658-9.	2.4	0
290	Institution of a standard procedure to prevent hepatic artery thrombosis. Liver Transplantation, 2009, 15, 659-61.	2.4	0
291	Does correcting hyponatremia improve liver transplant outcomes?. Liver Transplantation, 2009, 15, 811-3.	2.4	0
292	Follow-up on platelet transfusion causing decreased postoperative survival after liver transplantation. Liver Transplantation, 2009, 15, 814-5.	2.4	0
293	Should split-liver transplantation be avoided in critically ill adult recipients?. Liver Transplantation, 2009, 15, 1150-1.	2.4	0
294	Control of intraoperative glucose levels during liver transplantation to lower the incidence of surgical site infections. Liver Transplantation, 2009, 15, 1151-2.	2.4	0
295	Increasing CD4+FOXP3+ regulatory T cells in human liver allografts. Liver Transplantation, 2009, 15, 1152-3.	2.4	0
296	Is survival after liver transplantation for hepatocellular carcinoma influenced by the etiology of the liver disease?. Liver Transplantation, 2009, 15, 1367-8.	2.4	0
297	Should intraportal insulin administration become routine in clinical transplant care?. Liver Transplantation, 2009, 15, 1368-9.	2.4	0
298	Some liver transplant patients have reduced neutrophil activation: so what?. Liver Transplantation, 2009, 15, 1632-3.	2.4	0
299	What price do we pay for reconstruction of the hepatic arteries of deceased donors?. Liver Transplantation, 2009, 15, 1633-5.	2.4	0
300	Continuing search for the test to measure liver function capacity. Liver Transplantation, 2009, 15, 1635-6.	2.4	0
301	Optimizing Risk Assessment In Simultaneous Liver and Kidney Transplant: Donor and Recipient Factors Associated With Improved Outcome. Transplantation Proceedings, 2022, 54, 715-715.	0.6	0
302	Title is missing!. , 2020, 15, e0233610.		0
303	Title is missing!. , 2020, 15, e0233610.		0
304	Title is missing!. , 2020, 15, e0233610.		0
305	Title is missing!. , 2020, 15, e0233610.		0
306	Title is missing!. , 2020, 15, e0233610.		0

#	ARTICLE	IF	CITATIONS
307	Title is missing!. , 2020, 15, e0233610.		0
308	Title is missing!. , 2020, 15, e0233610.		0
309	Title is missing!. , 2020, 15, e0233610.		0